1. Ossio closed a $38.5 million in financing to help accelerate adoption of the Ossiofiber intelligent bone regeneration technology.
2. Janet Conway, MD, completed the first U.S. cases using Bonesupport’s Cerament G for osteomyelitis.
3. Bone Biologics and the University of California Los Angeles plan to begin their joint venture clinical trial testing the efficacy of their bone graft substitute treatment for spinal fusion, trauma, osteoporosis and other bone-related indications in 2023.
4. Swedish-based bone graft substitute manufacturer Bonesupport found its Cerament G can save patients an average $28,000.
5. Shriners Children’s Hawaii in Honolulu is the first hospital in the state to use the Bridge-Enhanced ACL Restoration, or BEAR, implant.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.